This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

10-11 December, 2024

LIVE Online Course

10-11 December, 2024

LIVE Online Course

Learn how to successfully design, implement and report bioavailability and bioequivalence studies for different formulation types

Course Overview

Bioavailability (BA) is defined as the rate and extent to which the unchanged active substance is absorbed and becomes available in the systemic circulation. Understanding bioavailability is essential during drug development as it is one of the fundamental properties of drug formulation. Information on bioavailability is also used to determine bioequivalence (BE) when submitting a generic dossier.

Through interactive sessions and multiple case studies, this course will evaluate every aspect of BA/BE from the regulations and types of protocol studies to bioanalysis, statistical analysis and reporting. Once completed you will have a solid understanding of bioavailability, supporting you in drug development. You will also have the confidence to develop and implement your own bioequivalence studies to ensure speedy generic approval.

The course will also examine key aspects of biowaivers such as the regulatory hurdles, types of biowaivers and data needed so you can save money and time with fast biowaiver applications.

Live Online Training Course

Gain real-time access to a subject matter expert delivering online training in a structured virtual classroom environment.
Students will learn through:

  • Live interactive sessions
  • Direct interaction with the trainer during live sessions
  • Participation in interactive features within sessions including polls, Q&A, break out rooms, tasks, case studies, and more
  • Interaction with peers during live sessions and through the online forum

Timings and dates are subject to change - final confirmation will be provided with login details. Delegates will receive login instructions two days prior to the course start date. If you have any questions please contact melanie.epstein@informa.com.

What will you learn?

Key Definitions

Understand the fundamentals of bioavailability, bioequivalence and biowaivers

BA/BE study

Determine when a BA/BE study is obligatory

BA/BE protocol studies

Identify the various BA/BE protocol studies that are used

Design Studies

Develop strategies for testing highly variable drugs and design studies for different types of formulation

Bioanalytical method validation and requirements

Examine bioanalytical method validation and requirements in the US and EU

Pharmacokinetic parameters calculation

Learn to calculate pharmacokinetic parameters on various types of studies and formulations

Bioequivalence regulations

- Assess the regulations in the EU, US, Russia, Brasil, China and Japan for bioequivalence studies to gain a global perspective and maintain compliance

Biowaiver regulations

Learn to interpret biowaiver regulations in the US and EU and meet compliance

Evaluation

Evaluating the risk associated with submitting a biowaiver

Who is this course for?

For professionals working in clinical drug development who formulate drugs. It is also a good course for those who work in QA in generic companies. Regulators would be interested due to BE data being used in variation applications.

Regulatory Affairs

International Project Manager

Medac GmbH

The trainer was very experienced with many examples and encouraged time for questions.